Karyopharm Therapeutics
KPTI
KPTI
171 hedge funds and large institutions have $637M invested in Karyopharm Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 57 increasing their positions, 57 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
171
Holders Change
+3
Holders Change %
+1.79%
% of All Funds
3.01%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
28
Increased
57
Reduced
57
Closed
24
Calls
$2.61M
Puts
$3.95M
Net Calls
-$1.34M
Net Calls Change
-$4.58M
Top Buyers
| 1 |
Two Sigma Investments
New York
|
+$15.3M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$11.2M |
| 3 |
Morgan Stanley
New York
|
+$10.1M |
| 4 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$8.73M |
| 5 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$8.73M |
Top Sellers
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$20.1M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$18.7M |
| 3 |
Millennium Management
New York
|
-$18.5M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$17.3M |
| 5 |
D.E. Shaw & Co
New York
|
-$14.3M |
